Men with BRCA1 and BRCA2 gene mutations should be given annual prostate cancer screening checks, leading scientists have said ...

One of the biggest challenges in cancer treatment is chemoresistance: Tumors that initially respond well to chemotherapy ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

Zydus Lifesciences Ltd announced on Friday (November 7) that it has received tentative approval from the US Food and Drug ...

With breast cancer on both sides of the family, a 29-year-old Utah attorney opted to reduce her own risk drastically.

Prostate cancer guidelines should change so that all men from the age of 40 with mutations in either the BRCA1 or BRCA2 gene are offered regular PSA testing to detect early signs of the disease, ...

One of the biggest challenges in cancer treatment is chemoresistance: tumors that initially respond well to chemotherapy become resistant over time ...

This insightful review explores key areas of cancer genetic research, focusing on genes that may benefit from ...

Leading scientists are advocating for annual prostate cancer screening for men with BRCA1 and BRCA2 gene mutations. Experts at the London-based Institute of Cancer Research (ICR) state that the ...

FORMS, AND YOU MAY HAVE HEARD OF SOME GENE MUTATIONS LIKE BRCA1 OR BRCA2, BUT THERE’S ANOTHER ONE THAT YOU MAY NOT HAVE HEARD OF, AND IT’S CHEK2. MERCY MEDICAL CENTER DOCTOR NEIL FRIEDMAN JOINS US NOW ...

Zydus Lifesciences announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Olaparib Tablets, used in the treatment of certain cancers.